Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10373935 | 0.84 | ALDH1A1 (0.45) | ALDH1A1POLBDRD3KEAP1TAAR1 | |
| SCHEMBL3057133 | 0.83 | ALDH1A1 (0.44) | ALDH1A1POLBDRD3KEAP1TAAR1 | |
| SCHEMBL8862542 | 0.76 | ALDH1A1 (0.38) | ALDH1A1POLBKEAP1TAAR1 | |
| SCHEMBL8950105 | 0.75 | ALDH1A1 (0.39) | ALDH1A1POLBTAAR1 | |
| SCHEMBL9079085 | 0.73 | ALDH1A1 (0.35) | ALDH1A1POLBKEAP1TAAR1 | |
| SCHEMBL470176 | 0.70 | KEAP1 (0.38) | ALDH1A1POLBDRD3KEAP1TAAR1 | |
| SCHEMBL6420253 | 0.68 | KEAP1 (0.37) | ALDH1A1POLBDRD3KEAP1TAAR1 | |
| SCHEMBL6757801 | 0.68 | KEAP1 (0.37) | ALDH1A1POLBDRD3KEAP1TAAR1 | |
| SCHEMBL3101559 | 0.68 | ALDH1A1 (0.40) | ALDH1A1POLBDRD3KEAP1TAAR1 | |
| SCHEMBL3012768 | 0.67 | NPC1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
| WO-1996022099-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5538966-A | ENZYME INHIBITORS FOR TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1995019981-A1 | THIENOTHIAZINE SULFONAMIDE DERIVATIVES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS CARBONIC ANHYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0177163-B1 | HERBICIDAL ACETALS AND KETALS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4861366-A | Herbicidal acetals and ketals | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-29 | — | — | US | disclosed |
| US-4753672-A | FURAN-, THIOPHENE-, PYRAZOLE-, PYRIDINE- OR BENZENE-SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-06-28 | — | — | US | disclosed |
| US-4659369-A | Herbicidal acetals and ketals | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-04-21 | — | — | US | disclosed |
| EP-0177163-A2 | Herbicidal acetals and ketals | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885POLB 3933/4885DRD3 58/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | ALDH1A1 2206/4885POLB 3888/4885DRD3 3938/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885POLB 3933/4885DRD3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.